Physician profile
Joseph M Bailey
NPI 1396774717
$3,050.27
in general payments reported to CMS, 2019-2025
23 companies · $575 in 2025
The $575 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $335 · 2021: $476 · 2022: $495 · 2023: $410 · 2024: $425 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $513.93 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $331.30 | 2019-2025 | Bexsero, Penmenvy |
| Merck Sharp & Dohme LLC | $285.30 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $248.70 | 2020-2025 | Elaprase |
| Pfizer INC. | $238.59 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $223.14 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $209.53 | 2020-2024 | Doc Band |
| Kaleo, INC. | $154.66 | 2019-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $138.27 | 2022-2025 | |
| Adlon Therapeutics L.P. | $126.78 | 2020-2021 | |
| Neos Therapeutics, LP | $123.91 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $88.91 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $84.28 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $58.73 | 2021-2025 | Qelbree |
| Shire North American Group INC | $40.09 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $37.70 | 2019 | |
| Seqirus USA INC | $35.38 | 2021-2022 | |
| Covis Pharma Gmbh | $27.57 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.61 | 2025 | Bylvay |
| Sobi, INC | $17.09 | 2023 | |
| Tris Pharma INC | $15.73 | 2023 | Dyanavel Xr |
| Phadia US INC. | $14.58 | 2019 | |
| Circassia INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.